Fatigue is not associated with raised inflammatory markers in multiple sclerosis
Iriarte, J.; de Castro, Pón.
Neurology 58(7): 1134; Author Reply 1134-5
2002
ISSN/ISBN: 0028-3878 PMID: 11940715 Document Number: 545794
Document emailed within 1 workday
Related Documents
Boerio, D.; Lefaucheur, J.P.; Hogrel, J. , Y.; Creange, A. 2006: Pathophysiology and treatment of fatigue in multiple sclerosis Revue Neurologique (Paris) 162(3): 311-320Watson, J.; Whiting, P.; Salisbury, C.; Banks, J.; Hamilton, W. 2020: Raised inflammatory markers as a predictor of one-year mortality: a cohort study in primary care in the UK using electronic health record data Bmj Open 10(10): E036027
Pedraz, B.; Sammer, G. 2018: The importance of glutamate in the neuro-endocrinological functions in multiple sclerosis, related to fatigue Revista de Neurologia 67(10): 387-393
Baĭdina, T.V.; Akintseva, I.V.; Trushnikova, T.N. 2014: A chronic fatigue syndrome and blood platelet serotonin levels in patients with multiple sclerosis Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 114(2 Part 2): 25-28
Łabuz-Roszak, B.; Kubicka-Baczyk, K.; Pierzchała, K.; Horyniecki, M.; Machowska-Majchrzak, A.; Augustyńska-Mutryn, D.; Kosałka, K.; Michalski, K.; Pyszak, D.; Wach, J. 2013: Quality of life in multiple sclerosis--association with clinical features, fatigue and depressive syndrome Psychiatria Polska 47(3): 433-442
Fauchet, R.; Madigand, M.; Gueguen-Duchesne, M.Y.; Papin, J.; Sabouraud, O.; Genetet, B. 1984: Complement markers Bf and C4 in multiple sclerosis Revue Neurologique (Paris) 140(6-7): 422-425
Ross, L.; Stevens, W.; Rabusa, C.; Wilson, M.; Ferdowsi, N.; Walker, J.; Sahhar, J.; Ngian, G.-S.; Zochling, J.; Roddy, J.; Tymms, K.; Major, G.; Strickland, G.; Proudman, S.M.; Nikpour, M. 2018: The role of inflammatory markers in assessment of disease activity in systemic sclerosis Clinical and Experimental Rheumatology 36 Suppl 113(4): 126-134
Landtblom, A.-M.; Flensner, G.; Callander, M.; Stawiarz, L. 2004: The Swedish MS registry points out an important clinical problem: physical and psychological fatigue is a main symptom in multiple sclerosis Lakartidningen 101(44): 3456-3457
Bartosik-Psujek, H.; Stelmasiak, Z. 2001: Biochemical markers of damage of the central nervous system in multiple sclerosis Annales Universitatis Mariae Curie-Sklodowska. Sectio D: Medicina 56: 389-392
Perron, H. 1998: MSRV retrovirus and gliotoxin protein: potential biological markers in multiple sclerosis? Annales de Biologie Clinique 56(4): 427-438
Leone, C.; Severijns, D.; Doležalová, V.; Baert, I.; Dalgas, U.; Romberg, A.; Bethoux, F.; Gebara, B.; Santoyo Medina, C.; Maamâgi, H.; Rasova, K.; Maertens de Noordhout, B.ît.; Knuts, K.; Skjerbaek, A.; Jensen, E.; Wagner, J.M.; Feys, P. 2016: Prevalence of Walking-Related Motor Fatigue in Persons with Multiple Sclerosis: Decline in Walking Distance Induced by the 6-Minute Walk Test Neurorehabilitation and Neural Repair 30(4): 373-383
Seifert, B. 2001: Muscle weakness, fatigue and raised transaminase values Praxis 90(45): 1980-1982
Schanke, A.K.; Grimsmo, J.; Sundet, K. 1995: Multiple sclerosis and prerequisites for driver's licence. A retrospective study of 33 patients with multiple sclerosis assessed at Sunnaas hospital Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 115(11): 1349-1352
Bykova, O.V.; Nankina, I.A.; Platonova, A.N.; Karpacheva, N.G.; Petrova, O.A.; Gorina, T.P.; Batysheva, T.T.; Serkov, S.V.; Kuzenkova, L.M. 2013: Differential diagnosis of multiple sclerosis with pediatric onset: the experience of the Moscow Division for treatment of children and adolescents with multiple sclerosis Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 113(10 Pt 2): 61-68
Laosanguanek, N.; Wiroteurairuang, T.; Siritho, S.; Prayoonwiwat, N. 2011: Reliability of the Thai version of SF-36 questionnaire for an evaluation of quality of life in multiple sclerosis patients in multiple sclerosis clinic at Siriraj Hospital Journal of the Medical Association of Thailand 94 Suppl. 1: S84-S88
Lyon-Caen, O.; Fontaine, B.; Gout, O.; Tourbah, A. 1994: Multiple sclerosis and other related inflammatory disorders of the central nervous system: differential diagnosis and treatment Acta Neurologica Belgica 94(2): 92-97
Shorr, J.; Ziser, A.; Hochstadt, F.; Ovadia, H.; Abramsky, O. 1982: Diagnostic value of cerebrospinal fluid oligoclonal immunoglobulins in multiple sclerosis and inflammatory disease of the nervous system Harefuah 103(10): 243-245
Reclos, G.J.; Baxevanis, C.N.; Sfagos, C.; Papageorgiou, C.; Tsokos, G.C.; Papamichail, M. 1987: Multiple sclerosis: II. Effects of prothymosin alpha on the autologous and allogeneic MLR in patients with multiple sclerosis Clinical and Experimental Immunology 70(2): 336-344
Bajramović, J.J.; Plomp, A.C.; Goes, A.v.; Koevoets, C.; Newcombe, J.; Cuzner, M.L.; van Noort, J.M. 2000: Presentation of alpha B-crystallin to T cells in active multiple sclerosis lesions: an early event following inflammatory demyelination Journal of Immunology 164(8): 4359-4366
Saida, T. 2004: Multiple sclerosis: treatment and prevention of relapses and progression in multiple sclerosis Rinsho Shinkeigaku 44(11): 796-798